100
Participants
Start Date
May 31, 2005
Primary Completion Date
March 31, 2013
Study Completion Date
March 31, 2013
Escitalopram
At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive escitalopram (same dose as received in Phase I) for an additional 6 months.
Placebo
At the end of the initial 14-week phase (open-label escitalopram), participants who responded to open-label escitalopram were randomly assigned to receive placebo for an additional 6 months.
Massachusetts General Hospital, Boston
Rhode Island Hospital, Providence
National Institute of Mental Health (NIMH)
NIH
Rhode Island Hospital
OTHER
Massachusetts General Hospital
OTHER